Prem S. Shah - Feb 16, 2024 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP and Pres-Pharm, Consumer W
Signature
/s/ Prem S. Shah
Stock symbol
CVS
Transactions as of
Feb 16, 2024
Transactions value $
-$2,267,947
Form type
4
Date filed
2/16/2024, 06:46 PM
Previous filing
Feb 14, 2024
Next filing
Feb 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Sale -$2.27M -29.5K -42.57% $76.95 39.8K Feb 16, 2024 Direct F1
holding CVS Common Stock (Restricted) 29.6K Feb 16, 2024 Direct
holding CVS ESOP Common Stock 4.79K Feb 16, 2024 Direct
holding CVS Stock Unit (deferred) 3.35K Feb 16, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Phantom Stock Credits 33.8K Feb 16, 2024 Common Stock 33.8K $1.00 Direct F3, F4
holding CVS Stock Option 846 Feb 16, 2024 Common Stock 846 $62.21 Direct F5
holding CVS Stock Option 9.47K Feb 16, 2024 Common Stock 9.47K $54.19 Direct F6
holding CVS Stock Option 28.6K Feb 16, 2024 Common Stock 28.6K $58.34 Direct F7
holding CVS Stock Option 26.6K Feb 16, 2024 Common Stock 26.6K $75.24 Direct F8
holding CVS Stock Option 28.7K Feb 16, 2024 Common Stock 28.7K $74.30 Direct F9
holding CVS Stock Option 41.6K Feb 16, 2024 Common Stock 41.6K $101.09 Direct F10
holding CVS Stock Option 89.1K Feb 16, 2024 Common Stock 89.1K $74.31 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between 76.93 to 76.99 per share.
F2 Consists of Stock Units awarded pursuant to Issuer's 2010 & 2017 Incentive Compensation Plans, the receipt of which the reporting person has elected to defer.
F3 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F4 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F5 Option became exercisable in four equal installments commencing 04/01/2019. Additional options from this award have been exercised.
F6 Option became exercisable in four equal installments commencing 04/01/2020. Additional options from this award have been exercised
F7 Option became exercisable in four equal installments commencing 04/01/2021. Additional options from this award have been exercised.
F8 Option became exercisable in three equal installments, commencing on 8/31/2021.
F9 Option became exercisable in three equal installments commencing 04/01/2022.
F10 Option became exercisable in four equal installments, commencing 4/1/2023.
F11 Option becomes exercisable in four equal annual installments, commencing 4/1/2024.